Level C· Early human research exploring benefitsRetrospective StudyEurope PMCOpen access

Clinical application of human umbilical cord-derived mesenchymal stem cells for small articular cartilage defects of the knee in military training-related injuries

Zhao G., Xue C., Li B., Jin W., Liu X.

Retrospective Study with a reported sample of 11 on Cartilage Damage, published in Pak J Med Sci (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Retrospective Study
Journal
Pak J Med Sci (2025)
Reported sample size
11
Source database
Europe PMC
PMID
40980389
PMCID
PMC12444110
DOI
10.12669/pjms.41.8.10803

Abstract (original English)

Objective To explore the short-term efficacy and safety of umbilical cord-derived mesenchymal stem cells(UC-MSCs) in patients with small articular cartilage defects of the knee. Methods This was a retrospective study from August 2020 to December 2020, thirty two patients with knee cartilage injuries caused by military training were admitted to the Department of Orthopedics in The General Hospital of North Theater Command Training Base included in the study. Group-A (n=11) underwent microfracture surgery, Group-B(n=10) underwent arthroscopic exploration and injected umbilical cord mesenchymal stem cells (UC MSCs) into the knee joint cavity, and Group-C (n=11) underwent microfracture surgery and injected UC MSCs into the knee joint cavity. Clinical data were collected from three groups of patients. Results The Lysholm scores of the three groups gradually increased, from 51.00 ± 1.6, 51.50 ± 2.2, and 50.91 ± 2.4 points before treatment to 74.64 ± 2.4, 79.40 ± 4.3, and 78.73 ± 4.2 points at the last follow-up (P 0.05). Conclusion The application of microfracture combined with UC MSCs injection or UC MSCs injection alone for small cartilage defects in the knee joint can achieve certain therapeutic effects in the short term, but as a new technology, stem cells need further observation for long-term efficacy.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research